Diagnostic utility of trefoil factor families for the early detection of lung cancer and their correlation with tissue expression

Minegishi,Kentaro; Dobashi,Yoh; Koyama,Teruhide; Ishibashi,Yuko; Furuya,Miki; Tsubochi,Hiroyoshi; Ohmoto,Yasukazu; Yasuda,Tomohiko; Nomura,Sachiyo

doi:10.3892/ol.2023.13725

Diagnostic utility of trefoil factor families for the early detection of lung cancer and their correlation with tissue expression

Authors:
- Kentaro Minegishi
- Yoh Dobashi
- Teruhide Koyama
- Yuko Ishibashi
- Miki Furuya
- Hiroyoshi Tsubochi
- Yasukazu Ohmoto
- Tomohiko Yasuda
- Sachiyo Nomura
View Affiliations

Affiliations: Department of Thoracic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Saitama 330‑8500, Japan, Department of Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Saitama 330‑8500, Japan, Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, Kyoto, Kyoto 602‑8566, Japan, Department of Surgery, Breast Surgery, Tokyo Women's Medical University, Adachi Medical Center, Adachi, Tokyo 123‑8558, Japan, Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo 113‑8655, Japan, Department of Thoracic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Saitama 330‑8500, Japan, Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Tokushima 770‑8505, Japan
Published online on: February 21, 2023 https://doi.org/10.3892/ol.2023.13725
Article Number: 139
Copyright: © Minegishi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Trefoil factors (TFFs) are upregulated in numerous types of cancer, including those of the breast, the colon, the lung and the pancreas, suggesting their potential utility as biomarkers for screening. In the present study, the clinical relevance of serum or urinary TFFs as biomarkers were comprehensively evaluated and the correlation with TFF expression levels in lung cancer tissue was examined. Serum and urine were collected from 199 patients with lung cancer and 198 healthy individuals. Concentrations of serum and urinary TFF1, TFF2 and TFF3 were measured using ELISA and the potential of TFF levels to discriminate between cancer and non‑cancer samples was evaluated. In 100 of the cancer cases, expression of TFF1‑3 was analyzed using immunohistochemical staining of paraffin sections. Furthermore, the relationship between TFF levels and clinicopathological factors among these cancer cases was analyzed using immunohistochemistry of tissue specimens, quantified and statistically analyzed. While serum levels of all TFFs measured using ELISA were significantly higher in patients with lung cancer compared with those in healthy individuals, urinary TFFs were lower. Areas under the curve (AUC) of the receiver operating characteristic curves for serum/urinary TFF1, TFF2 and TFF3 were 0.709/0.594, 0.722/0.501 and 0.663/0.665, respectively. Furthermore, the combination of serum TFF1, TFF2, TFF3 and urinary TFF1 and TFF3 demonstrated the highest AUC (0.826). In the clinicopathological analysis, serum TFF1 was higher in the early pathological T‑stage (pTis/1/2) compared with the later stage (pT3/4) and TFF2 was higher in the pN0/1 than the pN2 group. With regards to the histological types, urinary TFF1 was higher in squamous cell carcinoma than adenocarcinoma (AC), but TFF2 tended to be higher in AC. Using immunohistochemical analysis, although TFF1 and TFF3 expression showed positive correlation with serum concentrations, TFF2 was inversely correlated. In conclusion, serum and urinary TFF levels are promising predictive biomarkers, and their measurements provide a useful in vivo and non‑invasive diagnostic screening tool. In particular, TFF1 and TFF3 could be surrogate markers of clinicopathological profiles of human lung cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
3	Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
5	Chen ZQ, Huang LS and Zhu B: Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer. Dis Markers. 2018:98451232018. View Article : Google Scholar : PubMed/NCBI
6	Wen Z, Huang Y, Ling Z, Chen J, Wei X, Su R, Tang Z, Wen Z, Deng Y and Hu Z: Lack of efficacy of combined carbohydrate antigen markers for lung cancer diagnosis. Dis Markers. 2020:47167932020. View Article : Google Scholar : PubMed/NCBI
7	Lamy PJ, Grenier J, Kramar A and Pujol JL: Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer. 29:197–203. 2000. View Article : Google Scholar : PubMed/NCBI
8	Kjellev S: The trefoil factor family-small peptides with multiple functionalities. Cell Mol Life Sci. 66:1350–1369. 2009. View Article : Google Scholar
9	Thim L: Trefoil peptides: From structure to function. Cell Mol Life Sci. 53:888–903. 1997. View Article : Google Scholar
10	Xiao P, Ling H, Lan G, Liu J, Hu H and Yang R: Trefoil factors: Gastrointestinal-specific proteins associated with gastric cancer. Clin Chim Acta. 450:127–134. 2015. View Article : Google Scholar
11	Arumugam T, Brandt W, Ramachandran V, Moore TT, Wang H, May FE, Westley BR, Hwang RF and Logsdon CD: Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis. Pancreas. 40:815–822. 2011. View Article : Google Scholar : PubMed/NCBI
12	Rodrigues S, Rodrigue CM, Attoub S, Flejou JF, Bruyneel E, Bracke M, Emami S and Gespach C: Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells. Oncogene. 25:6628–6636. 2006. View Article : Google Scholar : PubMed/NCBI
13	Yusufu A, Shayimu P, Tuerdi R, Fang C, Wang F and Wang H: TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process. Int J Oncol. 55:789–804. 2019.
14	Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, et al: Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 12:1041–1053. 2010. View Article : Google Scholar
15	Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T and Lobie PE: Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res. 16:4292014. View Article : Google Scholar : PubMed/NCBI
16	Taupin DR, Kinoshita K and Podolsky DK: Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci USA. 97:799–804. 2000. View Article : Google Scholar : PubMed/NCBI
17	Ishibashi Y, Ohtsu H, Ikemura M, Kikuchi Y, Niwa T, Nishioka K, Uchida Y, Miura H, Aikou S, Gunji T, et al: Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer. Sci Rep. 7:48462017. View Article : Google Scholar : PubMed/NCBI
18	Ruibal A, Nunez MI, del Rio MC, Garcia Diez S, Rodriguez J and Alvarez De Linera JA: Cytosolic pS2 levels in 154 non-small-cell lung carcinomas. Correlation with other clinical and biological parameters. Rev Esp Med Nucl. 21:109–114. 2002.(In Spanish). View Article : Google Scholar
19	Amelung JT, Buhrens R, Beshay M and Reymond MA: Key genes in lung cancer translational research: A meta-analysis. Pathobiology. 77:53–63. 2010. View Article : Google Scholar : PubMed/NCBI
20	Ohshio G, Suwa H, Kawaguchi Y, Imamura M, Yamaoka Y, Yamabe H, Matsumoto M, Yoshioka H, Hashimoto Y and Takeda H: Differential expression of human spasmolytic polypeptide (trefoil factor family-2) in pancreatic carcinomas, ampullary carcinomas, and mucin-producing tumors of the pancreas. Dig Dis Sci. 45:659–664. 2000. View Article : Google Scholar
21	John R, El-Rouby NM, Tomasetto C, Rio MC and Karam SM: Expression of TFF3 during multistep colon carcinogenesis. Histol Histopathol. 22:743–751. 2007.
22	Dhar DK, Wang TC, Maruyama R, Udagawa J, Kubota H, Fuji T, Tachibana M, Ono T, Otani H and Nagasue N: Expression of cytoplasmic TFF2 is a marker of tumor metastasis and negative prognostic factor in gastric cancer. Lab Invest. 83:1343–1352. 2003. View Article : Google Scholar
23	Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, Kubota H and Nagasue N: Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res. 11:6472–6478. 2005. View Article : Google Scholar : PubMed/NCBI
24	Yamachika T, Werther JL, Bodian C, Babyatsky M, Tatematsu M, Yamamura Y, Chen A and Itzkowitz S: Intestinal trefoil factor: A marker of poor prognosis in gastric carcinoma. Clin Cancer Res. 8:1092–1099. 2002.PubMed/NCBI
25	Yang Y, Lin Z, Lin Q, Bei W and Guo J: Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: Recent progress and perspective. Cell Death Dis. 13:622022. View Article : Google Scholar : PubMed/NCBI
26	Babyatsky M, Lin J, Yio X, Chen A, Zhang JY, Zheng Y, Twyman C, Bao X, Schwartz M, Thung S, et al: Trefoil factor-3 expression in human colon cancer liver metastasis. Clin Exp Metastasis. 26:143–151. 2009. View Article : Google Scholar : PubMed/NCBI
27	Ahmed ARH, Griffiths AB, Tilby MT, Westley BR and May FEB: TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol. 180:904–916. 2012. View Article : Google Scholar
28	Buache E, Etique N, Alpy F, Stoll I, Muckensturm M, Reina-San-Martin B, Chenard MP, Tomasetto C and Rio MC: Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice. Oncogene. 30:3261–3273. 2011. View Article : Google Scholar : PubMed/NCBI
29	Bossenmeyer-Pourie C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L, Tomasetto C and Rio MC: The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol. 157:761–770. 2002. View Article : Google Scholar
30	Minegishi K, Dobashi Y, Tsubochi H, Hagiwara K, Ishibashi Y, Nomura S, Nakamura R, Ohmoto Y and Endo S: TFF-1 functions to suppress multiple phenotypes associated with lung cancer progression. Onco Targets Ther. 14:4761–4777. 2021. View Article : Google Scholar : PubMed/NCBI
31	Thompson AM, Elton RA, Hawkins RA, Chetty U and Steel CM: PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer. Br J Cancer. 77:492–496. 1998. View Article : Google Scholar : PubMed/NCBI
32	Uchino H, Kataoka H, Itoh H, Hamasuna R and Koono M: Overexpression of intestinal trefoil factor in human colon carcinoma cells reduces cellular growth in vitro and in vivo. Gastroenterology. 118:60–69. 2000. View Article : Google Scholar : PubMed/NCBI
33	Espinoza I, Agarwal S, Reddy A, Shenoy V, Subramony C, Sakiyama M, Fair L, Poosarla T, Zhou X, Shannon Orr W, et al: Expression of trefoil factor 3 is decreased in colorectal cancer. Oncol Rep. 45:254–264. 2021. View Article : Google Scholar : PubMed/NCBI
34	Huang Z, Zhang X, Lu H, Wu L, Wang D, Zhang Q and Ding H: Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: A monocentric cohort study in China. BMC Gastroenterol. 14:742014. View Article : Google Scholar
35	Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, Kubota K, Yamagata Y, Seto Y, Nakajima A, et al: Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology. 141:837–845. e1–7. 2011. View Article : Google Scholar : PubMed/NCBI
36	Vocka M, Langer D, Petrtyl J, Vockova P, Hanus T, Kalousova M, Zima T and Petruzelka L: Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer. Neoplasma. 62:470–477. 2015. View Article : Google Scholar
37	Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odicino FE, Pecorelli S and Santin AD: Trefoil factor 3: A novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer. 99:768–773. 2008. View Article : Google Scholar : PubMed/NCBI
38	Vestergaard EM, Borre M, Poulsen SS, Nexo E and Torring N: Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res. 12((3 Pt 1)): 807–812. 2006. View Article : Google Scholar : PubMed/NCBI
39	Im S, Yoo C, Jung JH, Choi HJ, Yoo J and Kang CS: Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: Correlation with clinicopathological parameters and prognosis. Int J Med Sci. 10:133–140. 2013. View Article : Google Scholar
40	Casado E, Garcia VM, Sanchez JJ, Gomez Del Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno Rubio J, Lopez RA, Garcia-Cabezas MA, et al: Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target. Int J Radiat Oncol Biol Phys. 84:1151–1158. 2012. View Article : Google Scholar : PubMed/NCBI
41	Li Q, Wang K, Su C and Fang J: Serum Trefoil Factor 3 as a protein biomarker for the diagnosis of colorectal cancer. Technol Cancer Res Treat. 16:440–445. 2017. View Article : Google Scholar
42	Qu Y, Yang Y, Ma D and Xiao W: Increased trefoil factor 3 levels in the serum of patients with three. Oncol Rep. 27:1277–1283. 2012. View Article : Google Scholar : PubMed/NCBI
43	Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
44	Dobashi Y, Tsubochi H, Matsubara H, Inoue J, Inazawa J, Endo S and Ooi A: Diverse involvement of isoforms and gene aberrations of Akt in human lung carcinomas. Cancer Sci. 106:772–781. 2015. View Article : Google Scholar
45	Ribieras S, Tomasetto C and Rio MC: The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta. 1378:F61–F77. 1998.
46	Xue H, Lu B, Zhang J, Wu M, Huang Q, Wu Q, Sheng H, Wu D, Hu J and Lai M: Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res. 9:545–555. 2010. View Article : Google Scholar : PubMed/NCBI
47	Chen RM, Chiou YS, Chong QY, Poh HM, Tan TZ, Zhang MY, Ma L, Zhu T, Pandey V, Basappa, Kumar AP and Lobie PE: Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK. Int J Mol Sci. 20:62152019. View Article : Google Scholar
48	Yusup A, Huji B, Fang C, Wang F, Dadihan T, Wang HJ and Upur H: Expression of trefoil factors and TWIST1 in colorectal cancer and their correlation with metastatic potential and prognosis. World J Gastroenterol. 23:110–120. 2017. View Article : Google Scholar
49	Xie H, Guo JH, An WM, Tian ST, Yu HP, Yang XL, Wang HM and Guo Z: Diagnostic value evaluation of trefoil factors family 3 for the early detection of colorectal cancer. World J Gastroenterol. 23:2159–2167. 2017. View Article : Google Scholar
50	Kaise M, Miwa J, Tashiro J, Ohmoto Y, Morimoto S, Kato M, Urashima M, Ikegami M and Tajiri H: The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: A new marker for gastric cancer risk. J Gastroenterol. 46:736–745. 2011. View Article : Google Scholar
51	Huang YG, Li YF, Wang LP and Zhang Y: Aberrant expression of trefoil factor 3 is associated with colorectal carcinoma metastasis. J Cancer Res Ther. 9:376–380. 2013. View Article : Google Scholar : PubMed/NCBI
52	Xiao L, Liu YP, Xiao CX, Ren JL and Guleng B: Serum TFF3 may be a pharamcodynamic marker of responses to chemotherapy in gastrointestinal cancers. BMC Clin Pathol. 14:262014. View Article : Google Scholar
53	Higashiyama M, Doi O, Kodama K, Yokuchi H, Inaji H and Tateishi R: Estimation of serum level of pS2 protein in patients with lung adenocarcinoma. Anticancer Res. 16:2351–2355. 1996.PubMed/NCBI
54	Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, Sykes AM, Aughenbaugh GL and Clemens MA: Lung cancer screening with CT: Mayo Clinic experience. Radiology. 226:756–761. 2003. View Article : Google Scholar : PubMed/NCBI
55	Sone S, Li F, Yang ZG, Honda T, Maruyama Y, Takashima S, Hasegawa M, Kawakami S, Kubo K, Haniuda M and Yamanda T: Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer. 84:25–32. 2001. View Article : Google Scholar : PubMed/NCBI
56	Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh GL, Zink FE, Hillman SL, Noetzel GR, et al: Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med. 165:508–513. 2002. View Article : Google Scholar : PubMed/NCBI
57	Manser RL, Irving LB, de Campo MP, Abramson MJ, Stone CA, Pedersen KE, Elwood M and Campbell DA: Overview of observational studies of low-dose helical computed tomography screening for lung cancer. Respirology. 10:97–104. 2005. View Article : Google Scholar : PubMed/NCBI
58	Pastorino U: Lung cancer screening. Br J Cancer. 102:1681–1686. 2010. View Article : Google Scholar : PubMed/NCBI
59	dos Santos Silva E, Ulrich M, Doring G, Botzenhart K and Gott P: Trefoil factor family domain peptides in the human respiratory tract. J Pathol. 190:133–142. 2000. View Article : Google Scholar
60	Wiede A, Jagla W, Welte T, Kohnlein T, Busk H and Hoffmann W: Localization of TFF3, a new mucus-associated peptide of the human respiratory tract. Am J Respir Crit Care Med. 159((4 Pt 1)): 1330–1335. 1999. View Article : Google Scholar : PubMed/NCBI
61	Wang DG, Johnston CF, Liu WH, Sloan JM and Buchanan KD: Expression of a breast-cancer-associated protein (pS2) in human neuro-endocrine tumours. Int J Cancer. 74:270–274. 1997. View Article : Google Scholar : PubMed/NCBI
62	Ruchaud-Sparagano MH, Westley BR and May FE: The trefoil protein TFF1 is bound to MUC5AC in human gastric mucosa. Cell Mol Life Sci. 61:1946–1954. 2004. View Article : Google Scholar
63	Otto WR and Thim L: Trefoil factor family-interacting proteins. Cell Mol Life Sci. 62:2939–2946. 2005. View Article : Google Scholar
64	Kouznetsova I, Laubinger W, Kalbacher H, Kalinski T, Meyer F, Roessner A and Hoffmann W: Biosynthesis of gastrokine-2 in the human gastric mucosa: Restricted spatial expression along the antral gland axis and differential interaction with TFF1, TFF2 and mucins. Cell Physiol Biochem. 20:899–908. 2007. View Article : Google Scholar : PubMed/NCBI
65	Sturmer R, Muller S, Hanisch FG and Hoffmann W: Porcine gastric TFF2 is a mucus constituent and differs from pancreatic TFF2. Cell Physiol Biochem. 33:895–904. 2014. View Article : Google Scholar : PubMed/NCBI
66	Hoffmann W: Trefoil factor family (TFF) peptides and their diverse molecular functions in mucus barrier protection and more: Changing the paradigm. Int J Mol Sci. 21:45352020. View Article : Google Scholar
67	Koh MJ, Shin DH, Lee SJ, Hwang CS, Lee HJ, Kim A, Park WY, Lee JH, Choi KU, Kim JY, et al: Gastric-type gene expression and phenotype in non-terminal respiratory unit type adenocarcinoma of the lung with invasive mucinous adenocarcinoma morphology. Histopathology. 76:898–905. 2020. View Article : Google Scholar : PubMed/NCBI
68	Ge H, Gardner J, Wu X, Rulifson I, Wang J, Xiong Y, Ye J, Belouski E, Cao P, Tang J, et al: Trefoil Factor 3 (TFF3) is regulated by food intake, improves glucose tolerance and induces mucinous metaplasia. PLoS One. 10:e01269242015. View Article : Google Scholar : PubMed/NCBI
69	Baus-Loncar M, Schmid J, Lalani el-N, Rosewell I, Goodlad RA, Stamp GW, Blin N and Kayademir T: Trefoil factor 2 (TFF2) deficiency in murine digestive tract influences the immune system. Cell Physiol Biochem. 16:31–42. 2005. View Article : Google Scholar : PubMed/NCBI
70	Itoh H, Tomita M, Uchino H, Kobayashi T, Kataoka H, Sekiya R and Nawa Y: cDNA cloning of rat pS2 peptide and expression of trefoil peptides in acetic acid-induced colitis. Biochem J. 318((Pt 3)): 939–944. 1996. View Article : Google Scholar : PubMed/NCBI
71	Xian CJ, Howarth GS, Mardell CE, Cool JC, Familari M, Read LC and Giraud AS: Temporal changes in TFF3 expression and jejunal morphology during methotrexate-induced damage and repair. Am J Physiol. 277:G785–G795. 1999.
72	Hoffmann W: Trefoil factor family (TFF) peptides and their links to inflammation: A Re-evaluation and new medical perspectives. Int J Mol Sci. 22:49092021. View Article : Google Scholar